| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 90,000 | 21 Jan 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LUDG | LUDWIG ENTERPRISES, INC. | 23 Jun 2025 | 0 | $0 | 3 | Director | 26 Jun 2025, 15:29 |
| IKT | Inhibikase Therapeutics, Inc. | 21 Jan 2025 | 4 | $0 | 4 | Chief Financial Officer | 22 Jan 2025, 16:05 |
| IKT | Inhibikase Therapeutics, Inc. | 03 Jan 2025 | 3 | $0 | 4 | Chief Financial Officer | 07 Jan 2025, 18:43 |
| IKT | Inhibikase Therapeutics, Inc. | 01 Apr 2024 | 1 | $0 | 4 | Chief Financial Officer | 02 Apr 2024, 17:14 |
| IKT | Inhibikase Therapeutics, Inc. | 01 Apr 2024 | 0 | $0 | 3 | Chief Financial Officer | 02 Apr 2024, 17:12 |